- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01860846
Anti-Tumor Necrosis Factor (TNF) Treatments, Work Productivity and Quality of Life in Crohn's Disease (IDEA)
31. mars 2017 oppdatert av: AbbVie
Improvement of Work Productivity and Quality of Life With Anti-TNF Therapies Used in Crohn's Disease in Routine Clinical Practice in Turkey
This multicenter, prospective, post marketing observational study (PMOS) was designed to demonstrate long-term effects of anti-Tumor Necrosis Factor therapies on Work Productivity and Impairment scales in participants with moderate to severe Crohn's Disease (CD) under routine conditions.
Secondary objectives of this study were long-term improvement of Quality of Life (QoL), evaluation of improvement of extraintestinal symptoms and comorbidities, and evaluation of safety.
Studieoversikt
Status
Fullført
Forhold
Detaljert beskrivelse
Male or female participants between 18 - 65 years of age with moderate to severe CD for whom the treating physician had recently initiated an anti-TNF treatment were included in this study.
Anti-TNF treatments were administered according to the treating physician's decision and applicable product label in Turkey.
No interventions were made to the treatment and the participant discontinuance or to the follow-up decisions of the treating physician.
Enrolled participants were observed for one year.
Studietype
Observasjonsmessig
Registrering (Faktiske)
106
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 65 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
Participants with Crohn's Disease who at the time of study entry were receiving anti-Tumor Necrosis Factor treatment as prescribed in accordance with Turkish Ministry of Health regulations and reimbursement conditions
Beskrivelse
Inclusion Criteria:
- Male or female participants between 18-65 years of age with moderately to severely (Crohn's Disease Activity Index 220-450) active Crohn's Disease with or without fistula formation
- Participants who were able to provide authorization to use and disclose information related to the study
- Proven diagnosis of Crohn's Disease in accordance with international diagnostic criteria such as European Crohn's and Colitis Organization (ECCO) guidelines
- Participants for whom the physician had initiated anti-Tumor Necrosis Factor treatment in accordance with Turkish Ministry of Health regulations and reimbursements
Exclusion Criteria:
- Participants who had a history of any kind of biological therapy and/or anti-Tumor Necrosis Factor treatments for Crohn's Disease or other indications
- Participants who had septic complications (active infection and/or active tuberculosis (TB), undrained abscess)
- Participants who had bowel obstructions and fibrotic strictures
- Participants who had received any investigational drug within 30 days prior to the Visit 1 at baseline
- For any reason, participants who were considered by the investigator to be unsuitable
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
---|
Participants with moderate to severe Crohn's Disease
Participants for whom the treating physician had recently initiated an anti-Tumor Necrosis Factor (TNF) treatment
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Work Productivity and Activity Index (WPAI): Absenteeism
Tidsramme: At baseline and 12 months
|
The Work Productivity and Activity Impairment: General Health (WPAI:GH) questionnaire was used to assess impairments in both paid work and unpaid work due to symptoms of Crohn's Disease.
The self-administered questionnaire consisted of 6 questions.
Question 2 asked participants to indicate the number of hours missed due to health problems in the past 7 days.
Question 4 asked participants to indicate the number of hours that they worked in the past 7 days.
Absenteeism (work time missed) was defined as the percentage of time absent from work due to health problems in the past week and was calculated by the formula Q2/(Q2 + Q4) × 100%.
WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
|
At baseline and 12 months
|
Work Productivity and Activity Index (WPAI): Presenteeism
Tidsramme: At baseline and 12 months
|
The Work Productivity and Activity Impairment: General Health (WPAI:GH) questionnaire was used to assess impairments in both paid work and unpaid work due to symptoms of Crohn's Disease.
The self-administered questionnaire consisted of 6 questions.
Question 5 asked participants the degree to which their health affected productivity while working in the past 7 days, on a scale ranging from 0 to 10, with 0 indicating that health problems had no effect on their work and 10 indicating that health problems completely prevented the participant from working.
Presenteeism (impairment at work) was calculated by the formula (Q5/10) × 100%.
WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
|
At baseline and 12 months
|
Total Work Productivity Impairment (TWPI)
Tidsramme: At baseline and 12 months
|
The Work Productivity and Activity Impairment: General Health (WPAI:GH) self-administered questionnaire was used to assess impairments in work due to symptoms of Crohn's Disease.
Q2 asked participants the number of hours missed due to health problems in the past 7 days.
Q4 asked participants the number of hours that they worked in the past 7 days.
Q5 asked participants the degree to which their health affected productivity while working in the past 7 days, on a scale ranging from 0 (health problems had no effect) to 10 (health problems completely prevented them from working).
Total work productivity impairment (TWPI) is the combined absenteeism and presenteeism for employed participants, the percentage of overall work productivity lost due to health problems.
TWPI was calculated using the formula Q2/(Q2+Q4)+[(1-(Q2/(Q2+Q4)))×(Q5/10)] × 100%.
WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
|
At baseline and 12 months
|
Total Activity Impairment (TAI)
Tidsramme: At baseline and 12 months
|
The Work Productivity and Activity Impairment: General Health (WPAI:GH) questionnaire was used to assess impairments in both paid work and unpaid work due to symptoms of Crohn's Disease.
The self-administered questionnaire consisted of 6 questions.
Question 6 asked participants to indicate the degree to which their health affected their regular activities in the past 7 days.
Total activity impairment is the percent impairment of non-work related activities due to health problems and was calculated with the formula (Q6/10) × 100%.
WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
|
At baseline and 12 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Change in Short Form 36 (SF-36) Health Survey Scores
Tidsramme: At baseline and 12 months
|
The Short Form 36 (SF-36) Health Survey was used to determine participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health.
Scores on each item were summed and averaged (range = 0 "worst" to 100 "best").
Increases from baseline indicate improvement.
|
At baseline and 12 months
|
Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Scores
Tidsramme: At baseline and 12 months
|
The Inflammatory Bowel Disease Questionnaire (IBDQ) is a 32-item self-administered questionnaire to measure health-related quality of life in adults with Crohn's Disease.
The 32 items are grouped into subscales: bowel-related symptoms (10 items), systemic symptoms (5 items), social function (5 items), and emotional function (12 items).
Responses to each item within each subscale range from 1 (significant impairment) to 7 (no impairment), and mean scores ranging from 1 to 7 are calculated for each subscale.
Higher scores indicate a better quality of life.
|
At baseline and 12 months
|
Change in Extra-intestinal Symptoms
Tidsramme: At baseline and 12 months
|
Extra-intestinal manifestations of Crohn's Disease (skeletal system [bones and muscle], dermatological [skin], hepatobiliary system [liver, gall bladder, and bile ducts], ocular [eyes] and oral [mouth]) were documented by the study investigators at each visit.
|
At baseline and 12 months
|
Number of Participants With Serious Adverse Events
Tidsramme: From the time of informed consent until 30 days or 5 half-lives following the last dose, up to 62 weeks
|
A serious adverse event was defined as any untoward medical occurrence in a clinical investigation participant that met at least 1 of the following criteria: death, life-threatening, hospitalization or prolongation of hospitalization, congenital anomaly, persistent or significant disability/incapacity, important medical event requiring medical or surgical intervention to prevent serious outcome, elective or spontaneous abortion.
|
From the time of informed consent until 30 days or 5 half-lives following the last dose, up to 62 weeks
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Hjelpsomme linker
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. mai 2013
Primær fullføring (Faktiske)
1. februar 2016
Studiet fullført (Faktiske)
1. februar 2016
Datoer for studieregistrering
Først innsendt
21. mai 2013
Først innsendt som oppfylte QC-kriteriene
21. mai 2013
Først lagt ut (Anslag)
23. mai 2013
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
16. juni 2017
Siste oppdatering sendt inn som oppfylte QC-kriteriene
31. mars 2017
Sist bekreftet
1. mars 2017
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- P13-338
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .